Brightpath Biotherapeutics filed an IND with the FDA to initiate a Phase I U.S. clinical trial of BP-2202 for multiple myeloma. The company’s submission is set to begin testing under NCT07667868. The IND marks an advance from earlier discovery and development work into early human evaluation for a malignancy that continues to attract new targets and modalities. For sponsors, Phase I initiation also unlocks trial enrollment momentum and safety characterization. While the report does not include BP-2202’s mechanism of action or initial dose-exposure plans, the filing itself indicates the compound has cleared key preclinical and CMC thresholds. For investors and pipeline analysts, the move adds another early-stage program to the crowded multiple myeloma landscape, increasing competition for efficacy signals in later phases.